Most Popular Human Cell in Science Gets Sequenced
By Ewen Callaway,
Nature
| 03. 15. 2013
The research world’s most famous human cell has had its genome decoded, and it’s a mess. German researchers this week report the genome sequence of the HeLa cell line, which originates from a deadly cervical tumour taken from a patient named Henrietta Lacks.
Established after Lacks died in 1951, HeLa cells were the first human cells to grow well in the laboratory. The cells have contributed to more than 60,000 research papers, the development of a polio vaccine in the 1950s and, most recently, an international effort to characterize the genome, known as ENCODE.
Previous work showed that HeLa cells, like many tumours, have bizarre, error-filled genomes, with one or more extra copies of many chromosomes. To get a closer look at these alterations, a team led by Lars Steinmetz, a geneticist at the European Molecular Biology Laboratory in Heidelberg, Germany, sequenced the popular 'Kyoto' version of the cell line and compared the sequence with that of a reference human genome. The team's results are published in G3.
Steinmetz’s team confirmed that HeLa cells contain one extra version of most...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...